ООО "ДКИС" - малая биофармацевтическая компания, разрабатывающая инновационное лекарство против Гепатита С на основе вирусоподобных частиц вируса гепатита С под названием ИСВАК™, полученных на основе инновационной технологии экспрессии сложных белков в эукариотических клетках

  • ООО "ДКИС" разработало инновационную вирусоподобную частицу вируса гепатита С (ВПЧ-ВГС) ИСВАК™ , имеющую уникальные иммуностимулирующие свойства, которые позволяют создать лекарство для лечения ВГС
  • Для создания ИСВАК™ в ООО "ДКИС" была разработана инновационная технология эукариотической экспрессии, которая может стать новой платформой экспрессии сложных белков в клетках ВНК-21
  • ООО «ДКИС» проводит двухуровневую стратегию развития препарата ИСВАК™, которая основана на клинических испытаниях в России, однако, осуществляет пилотное производство и доклинические испытания у опытных зарубежных вирусологов с целью сохранения глобального потенциала разработки

image.jpg

  • Technology

    Producing VLPs of coated viruses, such as Hepatitis C virus, is a complex technological feat. The key issue is achieving efficient expression of virus structural proteins in eukaryotic cell culture that would provide physiologically-relevant environment for VLP folding and post-translational modification. Formation of virus lipoprotein coating is complex process dependent on cellular environment. Existing technology of producing HCV-VLPs in insect cells failed to produce VLPs with useful properties, possibly due to differences of insect cell environment from the human cell one. We achieved efficient production of HCV-VLPs in BHK-21 cells that provide cell environment closest to that of human cells. In order to do that, we developed proprietary patented technology that employs replication enzymes of FMDV (foot-and-mouth disease virus) to replicate mRNA that codes for genes of HCV structural proteins in trans. In principle, this technology may be employed to express other genes of interest thus offering novel platform of eukaryotic expression. In additon, we developed useful biochemical technique of purification of HCV-VLP by PEG precipitation. Find out more about DKIS technology

  • Product

    Virus-like particles (VLPs) are useful biological nanoparticles that became fashionable product of modern biotechnology. They have several disctint potential applications ranging from pharmaceuticals to microelectronics. In the field of pharmaceuticals, VLPs may serve as vaccines or tools for delivering distinct agents to biological tissues. Revolutionary break-throughs recently happened in the immunological applications of uncoated virus VLPs, such as papillomavirus and adenovirus. However, these VLPs have certain disadvantages that warm the interest to obtaining novel coated VLPs. HCV-VLP, being the coated one, is of additional interest due to social importance of the underlying disease of Hepatitis C. Our product ISVAC™, that is HCV-VLP obtained in BHK-21 cells, appears to be the first coated VLP with useful properties, obtained in industrial fashion. ISVAC™ displays dramatic immunostimulatory activities that promice to become very useful in treating numerous deadly diseases, most notably hepatitis C and asthma. Find out more about DKIS product ISVAC™

  • Business plan

    DKIS LLC business plan is based on the contemporary model of pharmaceutical development that utilizes benefits of pharmaceutical development in emerging markets while preparing product for further development in global markets. This model calls for reaching clinical studies stage II in emerging markets and then moving into developed markets with strong data. Such approach allows utilizing significant time and cost savings that occur in emerging markets due to easier patient and professional recruitment. Still, this approach demands uphoding the highest quality and etical standards at each step of production and research. Find out more about DKIS business plan